Paloma Wang is partner and co-head of the firm’s China practice, focusing on capital markets and other corporate matters. She represents both issuers and underwriters in initial public offerings on the Hong Kong Stock Exchange, advising investors and corporate on private equity investments and listed issuers on compliance and general corporate and regulatory matters.
Ms. Wang has advised on numerous leading biotech IPOs in Hong Kong since the inception of the biotech regime in 2018, as well as counselling Hong Kong-listed biotech companies on ongoing corporate matters. She co-authors Skadden’s annual reports on Hong Kong-listed biotech companies, which provide a comprehensive overview of the market and annual developments since 2018.
Ms. Wang has been repeatedly named IPO Lawyer of the Year at Law.com International’s Asia Legal Awards (including in 2024). She also has been honored by Asian Legal Business as one of its Dealmakers of Asia in the China Dealmakers category, as well as by Asia Pacific Legal 500 as a Leading Individual.
Paloma Wang
